Imagine a world where crippling, life-threatening pancreatitis caused by sky-high blood fats could be a thing of the past. Sounds impossible? Think again. Israeli researchers have just helped develop a revolutionary treatment that slashes those dangerous blood fats by over 50%! It's a game-changer, but what does this really mean for people struggling with this condition? Let's dive in.
A groundbreaking international study, spearheaded in Israel by the brilliant Dr. Hofit Cohen from Sheba Medical Center, has revealed a new drug capable of dramatically reducing triglyceride levels – by more than half! But the real kicker? It also slashes the risk of developing excruciating and potentially fatal pancreatitis by up to a staggering 85%. This isn't just a small improvement; it's a seismic shift in how we approach this condition.
The results, which involved collaboration from nine Israeli medical centers, were recently published in the prestigious New England Journal of Medicine and presented at the American Heart Association's annual conference in New Orleans, solidifying the importance of this discovery.
Dr. Cohen, who directs the Lipid Disorders Diagnosis and Treatment Service at Sheba’s Strasburger Lipid Center, shared a powerful anecdote about a 50-year-old real estate appraiser whose life was transformed by this treatment. This patient had endured six agonizing pancreatitis episodes in recent years, requiring frequent hospitalizations, including stays in intensive care, despite adhering to strict diets, lifestyle changes, and taking the maximum doses of available medications. But here's the incredible part: after receiving the study treatment, his triglyceride levels normalized, and he hasn't needed emergency care since. That's the power of this new drug.
“This is a genuine breakthrough,” Dr. Cohen emphasized. “Until now, there was no truly effective treatment for patients grappling with extremely high triglyceride levels and recurrent pancreatitis. The study demonstrated a significant drop in triglycerides and a dramatic reduction in pancreatitis risk. This is a therapy that truly changes the course of these patients’ lives.”
But what exactly are triglycerides, and why are they so dangerous?
Triglycerides are a specific type of fat found in your blood. They consist of three fatty acids attached to a molecule called glycerol. After you eat, your intestines produce triglycerides and package them into particles called chylomicrons, which then travel through your bloodstream. Your liver also produces similar particles, known as VLDL (very-low-density lipoproteins). These triglyceride-rich particles are essential because they provide energy to your body or are stored in your fat tissue for later use. Think of them as fuel reserves.
Now, here's where it gets tricky. Normal triglyceride levels should be below 150 mg/dL (milligrams per deciliter). Levels between 150 and 499 mg/dL are considered elevated, 500 to 999 mg/dL are significantly high, and anything soaring above 1,000 mg/dL is considered extremely high and poses a serious risk of pancreatitis, as well as cardiovascular disease. It’s like having a ticking time bomb in your bloodstream.
Elevated triglycerides dramatically increase the risk of developing atherosclerosis (hardening of the arteries), heart attacks, strokes, and peripheral vascular disease. And very high levels sharply increase the risk of acute pancreatitis, a potentially life-threatening condition that often requires intensive care and can cause permanent damage to the pancreas. Imagine the constant worry and fear of another attack.
Dr. Cohen explained that elevated triglycerides usually stem from a combination of genetic predisposition and environmental factors. Unhealthy dietary habits, like consuming diets rich in fats and simple carbohydrates, a sedentary lifestyle (lack of exercise), excessive alcohol consumption, uncontrolled diabetes, kidney dysfunction, hypothyroidism (underactive thyroid), overproduction of cortisol, and central obesity (excess fat around the abdomen) are all significant contributors. In some cases, rare genetic disorders can impair the body's ability to break down triglycerides, leading to extremely high levels from a young age. This is a genetic lottery no one wants to win.
So, what are the current treatment options?
Typically, treatment begins with lifestyle modifications: adopting a balanced diet, reducing the intake of simple carbohydrates, abstaining from alcohol, engaging in regular exercise, and strictly controlling diabetes. Many patients also receive statins to lower their risk of heart disease. When triglyceride levels exceed 500 mg/dL, doctors often add fibrates or high-dose omega-3 fatty acids, which can lower triglycerides by 30% to 50%. But and this is the part most people miss... these treatments aren't always enough.
For some individuals, particularly those with levels “in the thousands,” these conventional measures simply don't cut it. They continue to suffer from recurrent pancreatitis despite diligently following their doctor's recommendations. In the most severe cases, patients undergo plasmapheresis, an invasive procedure that mechanically removes triglycerides from the blood. This process can be required weekly or biweekly, significantly impacting their quality of life.
However, in recent years, advanced RNA-based therapies have emerged, transforming the landscape of care for severe hypertriglyceridemia. These treatments specifically target proteins involved in triglyceride metabolism. One key protein, known as apoC-III, naturally slows down the breakdown of triglycerides. By suppressing its production, the body's ability to clear fats is significantly enhanced. It's like removing a roadblock in the body's fat-processing system.
Volanesorsen, the first drug in this class, received approval in Europe. The newer drug, Olezarsen, works through the same mechanism but is liver-targeted, making it potentially safer. The FDA approved it in 2024 for a rare genetic disease called familial chylomicronemia syndrome (FCS), and it is anticipated to become available in Israel soon. This is a major step forward for patients with this rare condition.
The CORE trials were designed to investigate whether Olezarsen could benefit adults with severe hypertriglyceridemia who had failed to achieve safe triglyceride levels despite lifestyle changes and conventional treatments. This was a crucial question to answer.
The two large, double-blind, placebo-controlled trials involved a total of 1,061 participants across 23 countries and approximately 140 medical centers, including nine in Israel. Participants received monthly injections of either Olezarsen or a placebo for one year. Researchers meticulously tracked changes in triglyceride levels and the incidence of pancreatitis. This rigorous study design ensured the reliability of the results.
The results were nothing short of remarkable: average triglyceride levels plummeted from approximately 800 mg/dL to reductions ranging from 50% to 70%, depending on the dosage. An astonishing 85% of patients achieved triglyceride levels below 500 mg/dL, and pancreatitis rates plummeted by more than 80%. These are truly life-altering outcomes.
The drug appeared to be generally safe, with similar rates of side effects and treatment discontinuation compared to the placebo group. However, researchers did identify several findings that require careful monitoring: mild increases in liver enzymes, reduced platelet counts in some patients (more common at higher doses), and dose-dependent increases in liver fat. Long-term follow-up studies are currently underway to further assess the long-term safety and efficacy of Olezarsen.
Dr. Cohen pointed out that, until now, patients with extremely high triglyceride levels often had no effective alternatives other than ongoing, invasive procedures like plasmapheresis. Olezarsen, she said, offers a life-changing option that dramatically lowers triglycerides, significantly reduces pancreatitis episodes, and may even eliminate the need for plasmapheresis altogether. This is a huge win for patients who have been suffering for years.
“This is a treatment that changes these patients’ lives,” she reiterated, calling it a true breakthrough and a “game changer” in the management of severe hypertriglyceridemia. She emphasized that combining the new drug with healthy lifestyle habits, diligent diabetes control, and existing therapies could significantly reduce illness and death among patients with dangerously high triglyceride levels.
Dr. Dov Gavish, chair of the Israel Atherosclerosis Society and a senior physician at Shaare Zedek Medical Center, added that the newer drugs available through clinical trials are already helping patients maintain far lower triglyceride levels, reduce pancreatitis episodes, and improve diabetes control. He also noted that more treatments are currently in development and “will allow us to offer even broader care and prevent severe complications.” The future of hypertriglyceridemia treatment looks brighter than ever.
Here's where things get interesting... While these results are overwhelmingly positive, some might argue that relying solely on medication without fully addressing lifestyle factors is a short-sighted approach. After all, diet and exercise play a crucial role in managing triglyceride levels. What are your thoughts? Should the focus be more on lifestyle changes first, or is aggressive drug therapy justified in severe cases? Also, considering the potential side effects like liver enzyme increases and platelet reduction, how do you weigh the risks versus the benefits of this new treatment? Share your opinions and experiences in the comments below!
